Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)
June 15, 2020 08:00 ET
|
Navidea Biopharmaceuticals, Inc.
DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic...